SCHEMBL3934353

SCHEMBL3934353

O=C(O)C1(C(=O)O)CCCCN1

nearest known ligand 0.36

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ARG1 P05089 1/20 0.34
ARG2 P78540 1/20 0.34
CYP2C19 P33261 1/20 0.33
AKR1C1 Q04828 1/20 0.31
FFAR3 O14843 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL774037 0.92 ARG1 (0.39) ARG1ARG2CYP2C19FFAR3
Hydrochloric Acid SCHEMBL16993455 0.90 ARG1 (0.38) ARG1ARG2FFAR3
SCHEMBL8993303 0.87 FFAR3 (0.31) ARG1ARG2FFAR3
SCHEMBL8371988 0.87 FFAR3 (0.31) ARG1ARG2FFAR3
SCHEMBL28200534 0.83
SCHEMBL4939341 0.80
SCHEMBL2900265 0.79 ARG1 (0.39) ARG1ARG2
SCHEMBL18076611 0.79 ARG1 (0.35) ARG1ARG2FFAR3
SCHEMBL18076610 0.79 ARG1 (0.35) ARG1ARG2FFAR3
SCHEMBL14246934 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105899487-B Method for producing 5-hydroxypiperidine-2-carboxylic acid 株式会社API 2018-10-19 CN disclosed
CN-107573277-A The manufacture method of the formic acid of 5 hydroxy piperidine 2 株式会社API 2018-01-12 CN disclosed
CN-105899487-A Method for producing 5-hydroxypiperidine-2-carboxylic acid 株式会社API 2016-08-24 CN disclosed
US-20150011541-A1 PIPECOLATE-SULFONAMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2015-01-08 US disclosed
EP-2797887-A1 PIPECOLATE-SULFONAMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2014-11-05 EP disclosed
WO-2013097947-A1 PIPECOLATE-SULFONAMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2013-07-04 WO disclosed
EP-2610245-A1 Pipecolate-sulfonamides for treatment of psychiatric disorders Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2013-07-03 EP disclosed
US-7572913-B2 Inhibitors of Rho kinase; N-Benzyloxycarbonyl-4-[N''-(tert-butyloxycarbonyl)hydrazino]piperidine; 4-{[N''-(tert-butyloxycarbonyl)-N'-(1'-propyl)]hydrazino}piperidine BIOAXONE THERAPEUTIQUE INC. (CA) 2009-08-11 US disclosed
EP-1720874-A1 4-SUBSTITUTED PIPERIDINE DERIVATIVES Bioaxone Therapeutique Inc. (CA) 2006-11-15 EP disclosed
US-20050272751-A1 4-Substituted piperidine derivatives BIOAXONE THERAPEUTIQUE INC. (CA) 2005-12-08 US disclosed
WO-2005080394-A1 4-SUBSTITUTED PIPERIDINE DERIVATIVES BIOAXONE THERAPEUTIQUE INC. (CA) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272751-A1 4-Substituted piperidine derivatives RHOC, PRPH, RHOT2 ARG1 94/4885ARG2 62/4885CYP2C19 4564/4885
US-20150011541-A1 PIPECOLATE-SULFONAMIDES FOR TREATMENT OF PSYCHIATRIC DISORDERS SYNGR2, SLC18A2, SLC6A3 ARG1 4491/4885ARG2 3713/4885CYP2C19 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.